At the recent #IGCS2024 conference, Dana-Farber’s Betsy Lee, MD, shared new data showing a combination of pembrolizumab and lenvatinib produced encouraging response rates in patients with recurrent clear cell ovarian cancer.

It's Symposium Day! We are very excited to host our THIRD annual scientific symposium #BRCAsymposium

We are kicking off our day with our keynote speaker Serena Nik-Zainal discussing mutational signatures, HRDetect and clinical applications! #BRCAsymposium

Dr. Sung from The Sung Lab at UTHSCSA discusses the function of BLM, BRCA1-BARD1 in End Resection

Dr. Talia Golan from Sheba Pancreatic Translational Lab discusses HR deficiency as a therapeutic target in pancreatic cancer #BRCAsymposium

Dr. Keyan Salari starts off our afternoon session discussing HR deficiency for early detection and management of prostate cancer #BRCAsymposium

Dr. Graeme Smith from Artios is speaking on development and preclinical evaluation of DNA polymerase theta inhibitors

Dr. Chris Lord from the Institute of Cancer Research #ICR discusses PARP inhibitor resistance and how to target it #BRCAsymposium

Starting the last afternoon sessions is Dr. Rugang Zhang from Rugang Zhang Lab on leveraging epigenetics to overcome PARP inhibitor resistance

Dr. Yizhou He from Chowdhury Lab and our 2023 David Livingston Early Career Investigator Award winner discusses overcoming PARPi resistance via BRCA1-dependent and BRCA1-independent HR #BRCAsymposium

Last but certainly not least Dr. Elizabeth Lee presents Phase 1 evaluation of trastuzumab deruxtecan with olaparib #BRCAsymposium

At #SABCS24 Dana-Farber’s Judy Garber, MD, MPH shared updated results from the OlympiA study showing addition of olaparib following standard therapy for BRCA+ breast cancer patients improved protection against recurrence & overall survival. Dana-Farber’s Breast Oncology Center bit.ly/41qC0MR

The MSCO Board of Directors has honored Geoffrey Shapiro MD PhD with this year's MSCO Distinguished Researcher Award. Congratulations, Geoffrey, on this notable recognition!

Congratulations to Judy Garber who is being honored by The Breast Cancer Research Foundation with the Carolyn Lynch Humanitarian Award!

Excited to share our publication out in Science today! We define a role for the CST complex in DSB repair pathway choice. This study was conducted in close collaboration with Patrick Sung’s lab. Congratulations to Michelle Swift and all other authors! science.org/doi/10.1126/sc…

First study of triplet combination of letrozole, abemaciclib, and metformin in any cancer type reported at #ASCO25. Panos Konstantinopoulos, MD, PhD, of Dana-Farber says the results of a phase 2 study in ER+ recurrent #endometrial cancer were encouraging.

Last week we had the chance to celebrate Dr. Panos Konstantinopoulos on his promotion to Professor of Medicine at Harvard Medical School! Congrats Dr. K🥳

.Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸, MD, FASCO, recently received the Advanced Clinical Research Award in Breast Cancer Research from Conquer Cancer, the ASCO Foundation. Lynce's work will focus on deciphering mechanisms of response to novel therapies in HER2 expressing stage III Inflammatory Breast Cancer, paving the

The EPIK-O trial tested a new combo therapy for tough-to-treat ovarian cancer without #BRCAmutations. While it didn’t show more benefit than chemo, researchers uncovered clues that could help personalize future treatments. #OvarianCancer #EPIKOtrial ascopubs.org/doi/10.1200/JC…

We're thrilled to announce our Annual Scientific Symposium on Nov. 11th at 8:30am EST! ✨ Join us in-person for a day of innovation and connection with leaders in the BRCA field. Learn more and get your tickets now: learn.hms.harvard.edu/programs/dana-… #BRCAsymposium25